These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21995285)

  • 1. Immunosuppressive monoclonal antibodies: current and next generation.
    Focosi D; Maggi F; Pistello M; Boggi U; Scatena F
    Clin Microbiol Infect; 2011 Dec; 17(12):1759-68. PubMed ID: 21995285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral infections associated with the clinical use of monoclonal antibodies.
    Gentile G; Foà R
    Clin Microbiol Infect; 2011 Dec; 17(12):1769-75. PubMed ID: 22023708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Monoclonal antibodies and therapeutics].
    Desgranges C
    Pathol Biol (Paris); 2004 Jul; 52(6):351-64. PubMed ID: 15261379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases.
    Cooper N; Arnold DM
    Br J Haematol; 2010 Apr; 149(1):3-13. PubMed ID: 20151975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The laboratory of clinical virology in monitoring patients undergoing monoclonal antibody therapy.
    Cavallo R
    Clin Microbiol Infect; 2011 Dec; 17(12):1781-5. PubMed ID: 22082209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
    Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
    Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS
    Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies in human organ transplantation and auto-immune diseases.
    Wijdenes J; Roy C; Morel-Fourrier B; Racadot E
    Therapie; 1992; 47(4):283-7. PubMed ID: 1494788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recommendations on tuberculosis and treatment of inflammatory bowel disease with infliximab. 2006 update].
    López-San Román A; Obrador A; Fortún J; Muñoz P; Gassull MA;
    Gastroenterol Hepatol; 2006 Feb; 29(2):81-4. PubMed ID: 16448610
    [No Abstract]   [Full Text] [Related]  

  • 10. Rituximab-associated infections.
    Gea-Banacloche JC
    Semin Hematol; 2010 Apr; 47(2):187-98. PubMed ID: 20350666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the off-label usage of rituximab in a large teaching hospital in New South Wales.
    Sharma R; Koller L; Barclay P; Liddle C
    Intern Med J; 2007 Aug; 37(8):569-71. PubMed ID: 17640190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New immunosuppressive therapies in renal transplantation: monoclonal antibodies.
    Buhaescu I; Segall L; Goldsmith D; Covic A
    J Nephrol; 2005; 18(5):529-36. PubMed ID: 16299678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks of combining immunosuppressive and biological treatments in inflammatory bowel disease.
    Roblin X; Phelip JM
    Arch Intern Med; 2008 Mar; 168(6):667; author reply 667-8. PubMed ID: 18362263
    [No Abstract]   [Full Text] [Related]  

  • 14. A review of the current use of rituximab in autoimmune diseases.
    Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR
    Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of monoclonal antibodies to achieve immunological tolerance.
    Waldmann H; Cobbold S
    Immunol Today; 1993 Jun; 14(6):247-51. PubMed ID: 8397765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tysabri risk causing headache for companies.
    Sheridan C
    Nat Rev Drug Discov; 2005 Sep; 4(9):703-4. PubMed ID: 16178114
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk factors for opportunistic infections in patients with inflammatory bowel disease.
    Toruner M; Loftus EV; Harmsen WS; Zinsmeister AR; Orenstein R; Sandborn WJ; Colombel JF; Egan LJ
    Gastroenterology; 2008 Apr; 134(4):929-36. PubMed ID: 18294633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressants.
    Marsh JW; Vehe KL; White HM
    Gastroenterol Clin North Am; 1992 Sep; 21(3):679-93. PubMed ID: 1516962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids.
    Kobashigawa J; David K; Morris J; Chu AH; Steffen BJ; Gotz VP; Gordon RD
    Transplant Proc; 2005 Mar; 37(2):1333-9. PubMed ID: 15848713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monoclonal antibodies in multiple sclerosis].
    Papeix C; Lubetzki C
    Med Sci (Paris); 2009 Dec; 25(12):1113-5. PubMed ID: 20035688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.